Navigation Links
Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Date:8/22/2008

ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"There is an urgent medical need for effective treatment options for non- small cell lung cancer because current treatment strategies have only a minimal impact on survival," said Joachim von Pawel, M.D., a principal investigator in the study from the Asklepios Fachkliniken Munchen-Gauting, Germany. "The majority of patients who are newly diagnosed with non-small cell lung cancer have locally advanced or metastatic disease that is currently incurable. We look forward to evaluating the potential of mapatumumab plus chemotherapy to offer a new approach to the first-line treatment of this deadly disease."

The NSCLC trial is a randomized, multi-center, open-label Phase 2 study to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and paclitaxel as first-line therapy in the treatment of advanced non-small cell lung cancer (Stage IIIB or IV). 111 patients have been randomly assigned to one of three treatment groups and treated with either the two-agent combination of carboplatin and paclitaxel or the three-agent combination of carboplatin, paclitaxel, and HGS-ETR1 at either 10 mg/kg or 30 mg/kg. HGS announced the initiation of the NSCLC trial In December 2007.

"A growing body of precl
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
2. ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. ProteoTechs Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimers Disease
5. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
6. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
7. New Research on Pre-Eclampsia in Mice May Have Important Implications for Humans
8. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
11. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., BOTHELL, Wash., Nov. 6 /PRNewswire-FirstCall/ -...financial results for the three and nine months en... SCOLR Pharma,s President and CEO, said, "We conti...r 12-hour ibuprofen formulation. Several potential...time, personnel and external resources as they eva...
(Date:11/6/2009)..., ,, FORT WASHINGTON, Pa., Nov. 6 /PRNewsw...g Administration (FDA), McNeil Consumer Healthcare...luntary recall of a limited number of product lots...bottles, with the distinctive red EZ-OPEN CAP. McN...uncharacteristic smell or taste associated with th...
(Date:11/6/2009)..., MORRISTOWN, N.J., Nov. 6 /PRNewswire-FirstCall/...leading specialty pharmaceutical company, announce...hief executive officer, will provide an overview a...Suisse 18th Annual Healthcare Conference on Wednes...d Time. ,, This presentation will be webcast li...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Avalere Estimates Medicare Part D Donut Hole Will Be Obsolete in 2023 50579 1Avalere Estimates Medicare Part D Donut Hole Will Be Obsolete in 2023 50579 2Materials and Processes for Medical Devices Event Brings Clinicians Engineers Designers Together 50574 1Materials and Processes for Medical Devices Event Brings Clinicians Engineers Designers Together 50574 2Materials and Processes for Medical Devices Event Brings Clinicians Engineers Designers Together 50574 3Materials and Processes for Medical Devices Event Brings Clinicians Engineers Designers Together 50574 4Lung Cancer Alliance Praises Congresswoman Donna Christensen for Introduction of Legislation to Correct Healthcare Disparities 50569 1Lung Cancer Alliance Praises Congresswoman Donna Christensen for Introduction of Legislation to Correct Healthcare Disparities 50569 2
...s, a division of Wyeth (NYSE: WYE ), announced to...A) has issued an approvable letter for,the first-i...e treatment of,adult patients with community-acqui...he FDA requested that Wyeth provide,additional ana...L for the,treatment of patients with CAP with illn...
...development in treatment-experi...Mune, Inc.,(Nasdaq: ITMN ) today announced that i...evaluating ITMN-191, designated R7227 at Roche (SW...interferon alpha-2a) and,Copegus(R) (ribavirin) in...patitis C virus (HCV) genotype 1 infection., Inte...
Other Medicine Technology:Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 2Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 3Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 4Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 5Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 6InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 2InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 3InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 4
(Date:11/9/2009)... 16, researchers say , , MONDAY, Nov. 9 ...ted in the United States in recent years, rising b...as found. , However, the total number of injur...s whirlpools and spas -- remains fairly small at a...ies were caused by slips and falls, according to t...
(Date:11/9/2009)...-- Natural Nutrition announced today the acquisiti...holly owned subsidiary of Natural Nutrition. Natu...Corp. and the company will focus its efforts on th... is developing mobile application market places th...h is focused on multi platform apps designed to ru...
(Date:11/9/2009)...e-USNewswire/ -- Today,s dramatic vote in the U.S....r to meaningful health care reform. We are very pl...Act makes health care more accessible and affordab..., promoting preventive care and improving delivery...r reminder of the tremendous amount of work we sti...
(Date:11/9/2009)...use calls now available in New York City by pain m...w York, NY (PRWEB) November 9, 2009 -- Davis Breg...routine house calls to residents of Manhattan in N...house call by calling the office at 212-918-1629 ...onvenience of being able to see the doctor in the ...
(Date:11/9/2009)...site providing support and information to victims ...TheFaceofLungCancer.org. The site provides a commu...portant information and advocating change in healt...November 9, 2009 -- With health care as the number...n of November’s designation as Lung Cancer A...
Breaking Medicine News(10 mins):Health News:Hot-Tub Injuries on the Rise 2Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:The Face of Lung Cancer Support and Information Website Launches to Increase Awareness and Advocacy 2Health News:The Face of Lung Cancer Support and Information Website Launches to Increase Awareness and Advocacy 3
...ificial heart was approved by the U.S. Food and Dr...al heart has been approved for patients with sever...plant. Under the FDA's Humanitarian Use Device... per year. The usage of this artificial heart is r...
... about 300 million poultry next month against bird...ls in the midst of large-scale criticism over the ...nced that the government plans of mass vaccination...rged Jakarta to give precedence for controlling th...
...em that could help in determining the condition of...do Silvio Nu?o Almirantearena has developed a new ...rt attack, brain stroke or high blood pressure, by...agnosis of the condition of the arterial system in...
...of Clinical Investigation and the September issue ... Monash University have reported that a new drug h...nd heart attacks by improving the blood flow in di... of the arteries. The finding is a significa...
... Zero after 9/11 are struggling with serious healt...to advocates.// "When we were needed on 9/11, no o...re anymore," said Lucelly Gil, who was present in ... necessary protection. "All of us who worked in th...
...t it has asked EU health authorities to re-examine...reatment Tarceva.// The European Committee for Me... rejected the Tarceva application. "People wi...ady been approved for this indication in the US," ...
Other Medicine News:Health News:First Implantable artificial heart gets FDA’s approva 2Health News:Indonesia To Conduct Mass Vaccination Of Poultry 2Health News:A New System Developed For Studying The Condition Of The Human Arterial System 2Health News:A New Drug That Could Revolutionize Management Of Heart Disease 2
...r the control of glucose metabolism. It is synthe...s the precursor, proinsulin, which is processed to... equimolar amounts into the portal circulation. T...ypeptide chains, the A-chain and B-chain (21 and 3...
...reatic -cell function is not only of use in the pr...y of diabetes mellitus, but is also relevant in cl...f treatment. Peripheral insulin levels cannot be u...and variable uptake from the portal circulation in...
...eimmunoassay for the quantitation of 25-OH D and o...Calibrators, controls and samples are diluted with...incubated in microtitre wells which are coated wit...ours at room temperature before aspiration and was...
...r the control of glucose metabolism. It is synthe...s the precursor, proinsulin, which is processed to... equimolar amounts into the portal circulation. T...ypeptide chains, the A-chain and B-chain (21 and 3...
Medicine Products: